Episurf Medical (NASDAQ: EPIS B) today announces that the company has reached another milestone by the planning of the 1,000th surgery with the Episealer® implant. Over 450 patients have had the implant for more than 2 years, and approximately 80 patients have passed 5 years since surgery. The majority are knee patients (Episealer® Knee), but the company is also executing on its early commercialization of the ankle implant, Episealer® Talus.

”I am very proud of the Episurf team today, and I would like to congratulate Prof. Ryd on this great achievement. Our history of strong clinical documentation and a solid operational experience creates a compelling combination for the future. We have satisfied customers, patients and counter-parties in a growing number of geographies, and we know that we are a market leader in a growing segment within orthopaedics,” says Pål Ryfors, CEO Episurf Medical.

“1,000 implants is a significant number. We are out of the cradle! As one of the founders of this endeavour, more than a decade ago, this is a cause for great satisfaction but also gratitude and relief. We can now say, for certain, that the Episurf technology delivers. The Episurf technology benefits hitherto unfulfilled needs. Finally, I would like to extend my gratitude to our shareholders for their support” says Prof. Leif Ryd, Senior Medical Advisor, Episurf Medical.